Alqaem and Biosign jointly announced the very successful public debut of the UFIT Heath Monitoring System at Arab Health 2011 in Dubai, UAE (Jan 24th – 27th), where for the first time, the features and benefits of the UFIT TEN-20 non-invasive blood pressure and blood glucose monitor were demonstrated to the public locally in the Gulf Region.
UFIT TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces pulse trace, blood pressure and blood glucose measurement results. UFIT TEN-20 does not require any type of blood sampling or under-skin implant. All measurements are indirect, noninvasive, and passive and do not produce any hazardous waste. The results are stored on Biosign servers along with the digital test sample. UFIT TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE Mark.
John Rizvi, Managing Director of Alqaem stated: “At Arab Health 2011 we received a lot of attention from key government leaders and retail partners from UAE, Saudi Arabia, Egypt and several other M.E.N.A. countries. We will now launch this remarkable system to clinical and institutional clients, which will tend to maximize the productivity of each UFIT(R)PAD unit, and generate additional goodwill and media attention for both Alqaem and Biosign.”
Thursday, February 10- 2011 @ 10:38 UAE local time (GMT+4) Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of Mediaquest FZ LLC.